IN2014MN02496A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02496A
IN2014MN02496A IN2496MUN2014A IN2014MN02496A IN 2014MN02496 A IN2014MN02496 A IN 2014MN02496A IN 2496MUN2014 A IN2496MUN2014 A IN 2496MUN2014A IN 2014MN02496 A IN2014MN02496 A IN 2014MN02496A
Authority
IN
India
Prior art keywords
formula
compounds
useful
compound
preparation
Prior art date
Application number
Inventor
Robert William Scott
Justin Philip Vitale
Kenneth Stanley Matthews
Martin Gerald Teresk
Alexandra Formella
Jared Wayne Evans
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of IN2014MN02496A publication Critical patent/IN2014MN02496A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure provides processes for the preparation of a compound of formula I: (I) which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.
IN2496MUN2014 2012-06-05 2013-06-04 IN2014MN02496A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261655935P 2012-06-05 2012-06-05
US13/800,202 US9056860B2 (en) 2012-06-05 2013-03-13 Synthesis of antiviral compound
PCT/US2013/044148 WO2013184702A1 (en) 2012-06-05 2013-06-04 Synthesis of antiviral compound

Publications (1)

Publication Number Publication Date
IN2014MN02496A true IN2014MN02496A (en) 2015-07-17

Family

ID=49671039

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2496MUN2014 IN2014MN02496A (en) 2012-06-05 2013-06-04

Country Status (17)

Country Link
US (3) US9056860B2 (en)
EP (1) EP2855454B1 (en)
JP (3) JP6181169B2 (en)
KR (2) KR102206434B1 (en)
CN (2) CN107266428A (en)
AU (1) AU2013271772B2 (en)
BR (1) BR112014030365A2 (en)
CA (1) CA2875508C (en)
ES (1) ES2587782T3 (en)
HK (3) HK1208670A1 (en)
IL (2) IL235941B (en)
IN (1) IN2014MN02496A (en)
MX (1) MX350892B (en)
PT (1) PT2855454T (en)
RU (1) RU2636943C2 (en)
SG (1) SG11201408011SA (en)
WO (1) WO2013184702A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358979C2 (en) 2003-05-30 2009-06-20 Фармассет, Инк. Modified fluorinated nucleoside analogues
CN106166160A (en) 2011-09-16 2016-11-30 吉利德制药有限责任公司 For treating the compositions of HCV
US9056860B2 (en) * 2012-06-05 2015-06-16 Gilead Pharmasset Llc Synthesis of antiviral compound
US8969588B2 (en) 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
US20140212491A1 (en) 2013-01-31 2014-07-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN104211565A (en) * 2013-05-31 2014-12-17 浙江九洲药业股份有限公司 Preparation method of anti-hepatitis c medicine intermediate
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP2883876A1 (en) * 2013-12-16 2015-06-17 Actelion Pharmaceuticals Ltd. Stereoselective synthesis of substituted pyrrolidines
TW202014413A (en) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 Processes for preparing antiviral compounds
CN104513223B (en) * 2014-11-20 2017-07-14 上海众强药业有限公司 The preparation method of fluorenes ethanone derivatives
CN104513147B (en) * 2014-11-20 2016-05-11 上海众强药业有限公司 The preparation method of fluorenes ethanone derivatives
US20180009790A1 (en) * 2014-12-24 2018-01-11 Prasad Raju Vnkv Vetukuri An improved process for the preparation of hcv inhibitor
CN104530016A (en) * 2014-12-25 2015-04-22 上海泓博智源医药技术有限公司 Method for preparing Ledipasvir and intermediates of method for preparing Ledipasvir
AU2016217952A1 (en) 2015-02-13 2017-09-28 Sandoz Ag Pharmaceutical compositions comprising Ledipasvir and Sofosbuvir
WO2016145269A1 (en) 2015-03-12 2016-09-15 Teva Pharmaceuticals International Gmbh Solid state forms ledipasvir and processes for preparation of ledipasvir
CN104829599B (en) * 2015-03-17 2017-06-09 上海众强药业有限公司 The preparation method and the midbody compound for preparing Lei Dipawei of Lei Dipawei and its derivative
CN104788361B (en) * 2015-04-21 2017-06-30 杭州科巢生物科技有限公司 The synthetic method of the formic acid derivates of 5 azaspiros [2.4] heptane 6
WO2016199049A1 (en) * 2015-06-09 2016-12-15 Hetero Research Foundation Process for the preparation of ledipasvir
CN104926796A (en) * 2015-06-17 2015-09-23 南通常佑药业科技有限公司 Preparation method for novel NS5A inhibitor medicine
WO2016207915A1 (en) * 2015-06-26 2016-12-29 Mylan Laboratories Limited Process for the preparation of ledipasvir
CN105017228A (en) * 2015-07-03 2015-11-04 上海众强药业有限公司 Ledipasvir intermediate monosulfate, crystalline form thereof and preparation method therefor
CN104961733B (en) 2015-07-06 2019-04-09 上海众强药业有限公司 Lei Dipawei crystal form and preparation method thereof
KR101919194B1 (en) * 2015-09-15 2018-11-15 주식회사 엘지화학 Heterocyclic compound and organic light emitting device comprising the same
CN105237516B (en) * 2015-10-13 2018-01-02 厦门市蔚嘉化学科技有限公司 A kind of Lei Dipawei preparation method
CN105399657B (en) * 2015-10-21 2017-10-10 海门慧聚药业有限公司 Preparation of Ledipasvir key intermediate
WO2017072596A1 (en) * 2015-10-26 2017-05-04 Optimus Drugs (P) Ltd An improved process for the preparation of ledipasvir
CN105237384B (en) * 2015-11-06 2017-06-30 上海万溯化学有限公司 A kind of preparation method of polysubstituted fluorene derivative
CN106892905A (en) * 2015-12-17 2017-06-27 常州市勇毅生物药业有限公司 A kind of preparation method of Lei Dipawei
US20190062332A1 (en) * 2016-02-01 2019-02-28 Lupin Limited Process for the preparation of ledipasvir and intermediates thereof
WO2017145028A1 (en) * 2016-02-26 2017-08-31 Glenmark Pharmaceuticals Limited Process for preparation of ledipasvir
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017195147A1 (en) 2016-05-12 2017-11-16 Lupin Limited Process for the preparation of ledipasvir and intermediates thereof
CN106008316B (en) * 2016-06-17 2018-04-27 成都百事兴科技实业有限公司 A kind of method of synthesis Lei Dipawei chiral intermediates
CN105968040B (en) * 2016-06-29 2019-02-05 爱斯特（成都）生物制药股份有限公司 A kind of preparation method of Lei Dipawei intermediate
CN107641081A (en) * 2016-07-22 2018-01-30 江苏威凯尔医药科技有限公司 A kind of preparation method of pharmaceutical intermediate
CN106349229B (en) * 2016-08-25 2018-11-06 安徽华昌高科药业有限公司 The preparation method and midbody compound of Lei Dipawei intermediates
CN106632275B (en) * 2016-12-20 2018-03-06 上海同昌生物医药科技有限公司 The preparation method of Lei Dipawei a kind of and the intermediate for preparing Lei Dipawei
US10392370B2 (en) 2017-03-13 2019-08-27 Optimus Drugs Pvt Ltd Process for the preparation of Daclatasvir dihydrochloride and its intermediates
CN107488685A (en) * 2017-06-13 2017-12-19 南京方生和医药科技有限公司 (S) the enzymology preparation method of the carboxylic acid of 5 azaspiros [2.4] heptane 6 and its derivative
CN107879908A (en) * 2017-11-14 2018-04-06 安徽诺全药业有限公司 A kind of Lei Dipawei key intermediates and preparation method thereof
CN107954990A (en) * 2017-11-14 2018-04-24 安徽诺全药业有限公司 A kind of preparation method of Lei Dipawei
CN108753863A (en) * 2018-06-14 2018-11-06 慎终（上海）生物科技有限公司 The synthesis technology of Lei Dipawei intermediates
EP3636637A1 (en) * 2018-10-10 2020-04-15 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (fasn)
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
EP3885339A1 (en) * 2020-03-27 2021-09-29 Rottapharm Biotech S.r.l. Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof
CN112851545B (en) * 2020-07-08 2022-09-20 日照巴洛特药业有限公司 Synthetic process of Ledipasvir intermediate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (en) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド High-throughput formation, identification and analysis of various solid forms
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7759337B2 (en) * 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
TWI410422B (en) * 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp Condensed tetrahydroquinoline derivative and its medical use
ES2391600T3 (en) * 2008-02-13 2012-11-28 Bristol-Myers Squibb Company Imidazoli biphenyl imidazoles as hepatitis C virus inhibitors
US8232409B2 (en) * 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
TWI689305B (en) 2009-05-13 2020-04-01 美商基利法瑪席特有限責任公司 Antiviral compounds
EP2475256A4 (en) * 2009-09-11 2013-06-05 Enanta Pharm Inc Hepatitis c virus inhibitors
US9296698B2 (en) * 2009-11-23 2016-03-29 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
AR084393A1 (en) 2010-06-10 2013-05-15 Gilead Sciences Inc METHODS TO TREAT HEPATITIS C VIRUS, COMPOSITION, USE, COMBINATION, KIT AND ONE OR MORE ANTI HCV COMPOUNDS
US8969588B2 (en) 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
US9056860B2 (en) * 2012-06-05 2015-06-16 Gilead Pharmasset Llc Synthesis of antiviral compound

Also Published As

Publication number Publication date
CN104520293B (en) 2017-07-28
JP2018145200A (en) 2018-09-20
AU2013271772A1 (en) 2015-01-15
KR20150027158A (en) 2015-03-11
CA2875508C (en) 2021-05-04
MX2014014569A (en) 2015-05-11
PT2855454T (en) 2016-08-26
HK1245273A1 (en) 2018-08-24
JP6594487B2 (en) 2019-10-23
BR112014030365A2 (en) 2016-07-05
EP2855454B1 (en) 2016-05-25
CN107266428A (en) 2017-10-20
JP2017160262A (en) 2017-09-14
US9056860B2 (en) 2015-06-16
AU2013271772B2 (en) 2017-11-02
JP6356876B2 (en) 2018-07-11
IL235941A0 (en) 2015-02-01
HK1209124A1 (en) 2016-03-24
WO2013184702A1 (en) 2013-12-12
JP2015518892A (en) 2015-07-06
CA2875508A1 (en) 2013-12-12
JP6181169B2 (en) 2017-08-16
IL235941B (en) 2018-04-30
US20150232453A1 (en) 2015-08-20
KR102206434B1 (en) 2021-01-22
IL258327A (en) 2018-05-31
US20130324740A1 (en) 2013-12-05
US9718807B2 (en) 2017-08-01
RU2014150435A (en) 2016-07-27
US20160340345A1 (en) 2016-11-24
CN104520293A (en) 2015-04-15
KR20200066376A (en) 2020-06-09
RU2636943C2 (en) 2017-11-29
HK1208670A1 (en) 2016-03-11
SG11201408011SA (en) 2015-01-29
MX350892B (en) 2017-09-22
EP2855454A1 (en) 2015-04-08
ES2587782T3 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
IN2014MN02496A (en)
NZ726356A (en) Processes for preparing antiviral compounds
CR20130470A (en) QUINASE INHIBITORS RELATED TO PIRROLO [2,3-d] PYRIMIDINE THROMPOMIOSINE
PH12015502839A1 (en) Antiviral compounds
CR20140510A (en) NUCLEOSIDES OF URACILO SPYROOXETHANE
CO6831982A2 (en) Pyrazolo [4,3-d] pyrimidines useful as kinase inhibitors
CR20140132A (en) PIRROLOPIRIMIDINE AND PURINE DERIVATIVES
CR20140042A (en) INDAZOLES
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
MA35089B1 (en) Inhibitors of the production of leukotrienes of benzodioxane type
NZ720745A (en) Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
IN2014MN01521A (en)
EP2590649A4 (en) Process for the synthesis of substituted morphinans
IN2014DN00144A (en)
CR20140322A (en) NEW BENCIL SULFONAMIDE DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS
MX2014014138A (en) New process for the preparation of 2-cyclopentyl-6-methoxy-isonic otinic acid.
MX342273B (en) Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-yl methyl-indol-1-yl)-acetic acid esters.
JO3196B1 (en) Process for the preparation of the l-arginine salt of perindopril
CR20150087A (en) DERIVATIVES OF PIRAZOL-CARBOXAMIDA
JOP20180012A1 (en) Sulfonylation process using nonafluorobutanesulfonyl fluoride
MY191759A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
MX2016007186A (en) Novel method for the synthesis of agomelatine.
MX363944B (en) Method of preparation of alphagalactosyl ceramides compounds.
IN2015DN02514A (en)
MX337610B (en) Processes for the preparation of (r)-2-acetamido-n-benzyl- 3-methoxypropionamide and intermediates thereof.